Immunic (NASDAQ:IMUX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Immunic (NASDAQ:IMUX) from a sell rating to a hold rating in a research note issued to investors on Saturday.

Several other brokerages have also issued reports on IMUX. Roth Capital restated a “buy” rating and issued a $19.00 price objective on shares of Immunic in a report on Thursday, May 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunic in a research report on Friday, May 29th. B. Riley Financial reduced their price target on shares of Immunic from $40.00 to $27.00 and set a “buy” rating on the stock in a research note on Friday, May 22nd. Lifesci Capital raised shares of Immunic to a “strong-buy” rating in a research note on Monday, May 4th. Finally, HC Wainwright restated a “buy” rating and issued a $22.00 price objective (up from $5.00) on shares of Immunic in a report on Thursday, April 30th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $47.25.

Immunic Stock Down 0.2%

NASDAQ:IMUX opened at $16.03 on Friday. Immunic has a 52 week low of $5.06 and a 52 week high of $16.86. The company has a market capitalization of $218.65 million, a P/E ratio of -3.66 and a beta of 1.41. The stock’s fifty day moving average is $14.53 and its two-hundred day moving average is $12.16.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.36. Sell-side analysts anticipate that Immunic will post -3.93 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Immunic

Several hedge funds have recently bought and sold shares of IMUX. Avidity Partners Management LP boosted its holdings in Immunic by 42.6% during the 1st quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company’s stock valued at $7,436,000 after acquiring an additional 2,000,000 shares during the period. CTC Alternative Strategies Ltd. purchased a new stake in Immunic during the first quarter worth about $27,000. Bank of America Corp DE increased its stake in Immunic by 80,724.2% during the first quarter. Bank of America Corp DE now owns 143,867 shares of the company’s stock worth $160,000 after purchasing an additional 143,689 shares during the period. ADAR1 Capital Management LLC purchased a new stake in Immunic during the first quarter worth about $33,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Immunic during the first quarter worth about $187,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.